Cargando…
Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65
Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induce...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827091/ https://www.ncbi.nlm.nih.gov/pubmed/29520229 http://dx.doi.org/10.3389/fphar.2018.00067 |
_version_ | 1783302426698186752 |
---|---|
author | Xu, JiaLi Feng, YaDong Song, GuoXin Gong, QiXing Yin, Li Hu, YingYing Luo, Dan Yin, ZhiQiang |
author_facet | Xu, JiaLi Feng, YaDong Song, GuoXin Gong, QiXing Yin, Li Hu, YingYing Luo, Dan Yin, ZhiQiang |
author_sort | Xu, JiaLi |
collection | PubMed |
description | Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induced epidermal Langerhans cell (LC) reduction via inhibition of LC migration. We conducted this study to investigate the effects of topical tacrolimus 0.03% ointment on high-dose UVB-irradiated human epidermal LCs. Methods: Twenty fresh human foreskin tissues were randomly divided into four groups as follows: Control, Tacrolimus (0.03%), UVB (180 mJ/cm(2)), and UVB (180 mJ/cm(2)) + Tacrolimus (0.03%). Four time points were set as follows: 0, 18, 24, and 48 h. We collected culture medium and tissues at each time point. The percentage of CD1a+ cells in the medium was detected by means of flow cytometry. Each tissue was prepared for immunohistochemistry, real-time quantitative PCR, and western blot. HaCaT cells were cultured and divided into four groups: Control, Tacrolimus (1 μg/ml), UVB (30 mJ/cm(2)), and UVB (30 mJ/cm(2)) + Tacrolimus (1 μg/ml). The cells were incubated for 24 h and prepared for real-time quantitative PCR and western blot. Results: Topical tacrolimus significantly reversed high-dose UVB irradiation-induced epidermal LC reduction and CD1a+ cell increment in culture medium. Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-α (TNF-α) and nuclear factor kappa B (NF-κB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus also significantly inhibited high-dose UVB irradiation-induced TNF-α expression in cultured tissues. Finally, TNF-α antagonist (recombinant human TNF-α receptor II: IgG Fc fusion protein) could significantly reverse UVB irradiation-induced epidermal LC reduction. Conclusion: Topical tacrolimus 0.03% could reverse UVB irradiation-induced epidermal LC reduction by inhibiting TNF-α secretion in keratinocytes via regulation of NF-κB/p65. |
format | Online Article Text |
id | pubmed-5827091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58270912018-03-08 Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 Xu, JiaLi Feng, YaDong Song, GuoXin Gong, QiXing Yin, Li Hu, YingYing Luo, Dan Yin, ZhiQiang Front Pharmacol Pharmacology Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induced epidermal Langerhans cell (LC) reduction via inhibition of LC migration. We conducted this study to investigate the effects of topical tacrolimus 0.03% ointment on high-dose UVB-irradiated human epidermal LCs. Methods: Twenty fresh human foreskin tissues were randomly divided into four groups as follows: Control, Tacrolimus (0.03%), UVB (180 mJ/cm(2)), and UVB (180 mJ/cm(2)) + Tacrolimus (0.03%). Four time points were set as follows: 0, 18, 24, and 48 h. We collected culture medium and tissues at each time point. The percentage of CD1a+ cells in the medium was detected by means of flow cytometry. Each tissue was prepared for immunohistochemistry, real-time quantitative PCR, and western blot. HaCaT cells were cultured and divided into four groups: Control, Tacrolimus (1 μg/ml), UVB (30 mJ/cm(2)), and UVB (30 mJ/cm(2)) + Tacrolimus (1 μg/ml). The cells were incubated for 24 h and prepared for real-time quantitative PCR and western blot. Results: Topical tacrolimus significantly reversed high-dose UVB irradiation-induced epidermal LC reduction and CD1a+ cell increment in culture medium. Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-α (TNF-α) and nuclear factor kappa B (NF-κB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus also significantly inhibited high-dose UVB irradiation-induced TNF-α expression in cultured tissues. Finally, TNF-α antagonist (recombinant human TNF-α receptor II: IgG Fc fusion protein) could significantly reverse UVB irradiation-induced epidermal LC reduction. Conclusion: Topical tacrolimus 0.03% could reverse UVB irradiation-induced epidermal LC reduction by inhibiting TNF-α secretion in keratinocytes via regulation of NF-κB/p65. Frontiers Media S.A. 2018-02-22 /pmc/articles/PMC5827091/ /pubmed/29520229 http://dx.doi.org/10.3389/fphar.2018.00067 Text en Copyright © 2018 Xu, Feng, Song, Gong, Yin, Hu, Luo and Yin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Xu, JiaLi Feng, YaDong Song, GuoXin Gong, QiXing Yin, Li Hu, YingYing Luo, Dan Yin, ZhiQiang Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 |
title | Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 |
title_full | Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 |
title_fullStr | Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 |
title_full_unstemmed | Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 |
title_short | Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65 |
title_sort | tacrolimus reverses uvb irradiation-induced epidermal langerhans cell reduction by inhibiting tnf-α secretion in keratinocytes via regulation of nf-κb/p65 |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827091/ https://www.ncbi.nlm.nih.gov/pubmed/29520229 http://dx.doi.org/10.3389/fphar.2018.00067 |
work_keys_str_mv | AT xujiali tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 AT fengyadong tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 AT songguoxin tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 AT gongqixing tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 AT yinli tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 AT huyingying tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 AT luodan tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 AT yinzhiqiang tacrolimusreversesuvbirradiationinducedepidermallangerhanscellreductionbyinhibitingtnfasecretioninkeratinocytesviaregulationofnfkbp65 |